Mayo Clinic company Anumana acquires cardiac AI company NeuTrace

Anumanaa partnership between EHR data company nference and the Mayo Clinic, announced this week that it had acquired NeuTrace, which focused on developing artificial intelligence applications for evaluating electrical signals in the heart.

The deal includes NeuTrace EP Data Biome, a platform designed to connect devices and AI tools to electrophysiology procedures, as well as AI applications in development aimed at improving accuracy and outcomes and reducing operative times.

As part of the acquisition, nference will have rights to use Data Biome outside of cardiovascular care.

Anumana plans to use the new features, along with nSights real-world evidence from nfercene, to integrate a patient’s EHR with electrocardiogram (ECG) and electrocardiogram (EGM). It said that using deep learning with ECG and EGM data, ECGs collected before and after procedures and medical record data could enable the development of AI algorithms that can detect heart disease earlier.

“Combining the power of NeuTrace’s EP Data Biome with EMR and other data methods on nSights platform nference has the potential to unlock game-changing AI applications in early cardiovascular disease detection, rhythm management and EP procedure safety, efficacy and efficiency, to improve long-term.” term,” Dr. Srijoy Mahapatra, president and chief executive officer of NeuTrace, said in a statement.

THE BIGGER EVOLUTION

Mayo Clinic and conference launched Anumana last year. The new project aims to use Mayo’s medical data and nference’s AI capabilities to build and commercialize new digital sensor diagnostics, first focusing on heart disease.

In May, Anumana announced that she had received it FDA breakthrough teaching device for ECG based artificial intelligence algorithm designed for early detection of pulmonary hypertension. While not subject to market approval, the program aims to accelerate the development and review of products that could more effectively treat or diagnose life-threatening or debilitating conditions.

It was also recently partnered with pharmaceutical company Novartis is developing artificial intelligence tools that analyze electrocardiograms to detect left ventricular dysfunction, which can lead to heart failure and atherosclerosis, which can cause heart attacks and strokes.

Leave a Comment

Your email address will not be published. Required fields are marked *